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therapies, bacteriophage cocktails. The value of such approaches
as well as the regulatory pathways are not clear yet. Poten-
tiating strategies have seen a resurgence in recent years and
are focused on blocking speciﬁc resistance mechanisms such as
beta-lactamases, resistance-regulating determinants, preventing
transfer of resistance plasmids or on protecting the microbiome,
disrupting bioﬁlms, targeting dormant bacteria, blocking virulence
factors, or supporting the immune system. In response to relaxed
regulatory requirements and economic incentives, recent years
have seen a trend towards reviving old drugs (e.g. fosfomycin,
fusidic acid, minocycline, aztreonam), modifying old drugs (e.g.
colistin) or potentiating old drugs (e.g. combination of approved
drugs, ß-lactamase-inhibitor combinations). These approacheswill
not solve our major problems with resistant bacteria but may buy
some time.
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Incentivizing antibiotic innovation
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Abstract: Antibiotic resistance can develop quickly. The CDC
demonstrated in2013 that theﬁrst reported cases of bacterial resis-
tance occurred in less than three years after market introduction of
sixkeyantibiotics. Yet antibiotic innovation isprogressingat amore
sedate pace, with only seven new classes of antibiotics launched
between 2000 and 2014 (Laxminarayan 2014). One reason for this
mismatch is that the pharmaceutical industry is not incentivized
to develop new antibiotics. Existing, generic antibiotics are inex-
pensive and still generally effective. New classes of antibiotics are
often necessary for only a small number of patients or as an insur-
ance mechanism for potential future outbreaks, making the return
on the sizeable investments in research and development insigniﬁ-
cant or negative. These poor returns encourage the pharmaceutical
industry to focus their efforts elsewhere. Yet resistance continues
to emerge, and if we wait until a major outbreak occurs, given the
long lead-times for developing a new antibiotic, it will be too late.
New incentives are necessary to stimulate greater antibiotic inno-
vation, and they must be linked to the sustainable and appropriate
use of the resulting antibiotic. Otherwise resistance may develop
faster. New incentives need to reward developers for their knowl-
edge generation, not the number of treatments sold. They also need
to ensure that patients receive the necessary antibiotic, regardless
of income status. These are fundamental changes to the current
reward system for pharmaceutical innovation. The EU-ﬁnanced
Innovative Medicines Initiative project, Driving reinvestment in
R&D for antibiotics and advocating their responsible use (DRIVE-
AB), is tasked with identifying new, sustainable economic models
as well as recommendations for a viable path forward to greater
antibiotic innovation.
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Abstract: Pragmatic strategies to improve antibiotic prescrib-
ing will be discussed in this session. Although a whole healthcare
economy approach to antibiotic stewardshipwill be advocated, the
particular focus will be within acute health care. Implementation
and adoption will be considered along with improvement meth-
ods in stewardship. Supporting organisational models will also be
reviewed and practical examples and case studiesdescribed. The
real and potential challenges faced in delivering effective antibiotic
stewardship and sustaining improvement will be discussed.
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Abstract: In recent years, deﬁnitive studies have demonstrated
the efﬁacy of the use of antiretroviral medications for primary
and secondary HIV prevention. The HPTN 052 trial enrolled 1,752
partners in HIV discordant couples in Africa, Asia and the Amer-
icas, and randomized the infected partner to receive immediate
versus deferred antiretroviral therapy. HIV-infected participants
who immediately initiated treatment were more than 96% less
likely to transmit HIV to their partners compared to those in the
delayed arm. The public health beneﬁt of early treatment has been
corroboratedbypopulation level studies correlatingdecreasingHIV
incidence in several areas of southern Africa with access to early
initiation of antiretrovirals. However, since the majority of peo-
ple living with HIV globally are unaware of their infection, and
less than 1/3 are virologically suppressed, new approaches to pri-
mary prevention for high risk seronegatives are also needed. Ten
randomized, controlled trials of antiretroviral pre-exposure pro-
phylaxis (PrEP) have been conducted, with studies in men who
have sex with men, heterosexual discordant couples, and injection
drug users ﬁnding that oral tenofovir-based regimens have been
effective in decreasing HIV incidence. Several studies of PrEP in
youngAfricanwomenhavenotdemonstratedefﬁcacy,while others
have,with variable levels ofmedication adherence explainingmost
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of the divergent ﬁndings. Tenofovir-emtricitabine taken orally for
PrEP has been approved by regulators in the US and Africa, and
is being considered for approval in several African and European
countries. New approaches to chemoprophylaxis are under study,
including the use of vaginal and rectal gels, vaginal rings, and
injectable agents. Because antiretroviral PrEP does not protect
against other sexually transmitted infections (STI), it must be given
as part of a comprehensive sexual health package, which includes
counseling and screening for treatable STI. Other interventions
that can decrease HIV transmission include adult male circumci-
sion of HIV-uninfectedmen, recreational drug treatment, including
access to clean syringes and other drug paraphernalia, and opi-
ate substitution therapy. The advent of new biomedically-based
prevention interventions does not obviate the need for behavioral
interventions, but suggests that counseling interventions should
incorporate reinforcement of medication adherence, as well as risk
reduction counseling.
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The good, the bad and the beautiful:
Anti-retroviral therapy considerations in
children and adolescents
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Abstract: HIV care for infants, children and adolescents has
improvedby leaps andbounds.Whereas the landscape twodecades
ago was bleak for children born with HIV who faced inevitable
death, it is now ﬁlled with hope with the ever-increasing access to
anti-retroviral therapy (ART) and care. Coupled with this progress
is the success of prevention ofmother-to-child transmission of HIV
interventions, again with ART, resulting in fewer new infections in
children. Yet, there is a long pathway to be traversed before we can
achieve complete control of pediatric HIV.
Challenges: Being born with HIV or acquiring HIV in childhood
can be devastating, even in the era of ART. Taking ART is a lifelong
practice; the risk of long-term adverse effects is real and lasting,
and children generally have to take ART for an average of 20 years
longer than an adult. This could mean constant monitoring, and in
many cases, life-threatening long-termconsequences. Adolescence
is a time when adherence to any treatment or norms established
earlier is questioned, and HIV care suffers the same fate. Rebellion
and poor adherence to ART results in risk of drug resistance and
treatment failure. Perinatally infected children may face mental
challenges, including learning disabilities and behavioral disorders.
Integrated with the social support offered for these challenges, one
also needs to maintain an honest and respectful discussion with
children about growing up with HIV, including their sexual and
reproductive health.
A hopeful future: The ambitious “90-90-90” goal launched by
UNAIDS in 2014 focuses not just on the 90% of the HIV-infected
population that they aim to diagnose and treat, but also on the 90%
of all treated who will be virologically suppressed. This shift in our
focus frommere volume of care, to actual quality of care in terms of
retentionandsuppression, arekey tooptimalHIVoutcomes.Nelson
Mandela once said, “There can be no keener revelation of a society’s
soul than theway it treats its children.” The know-how and tools that
are available in today’s world offer the global community the very
real and beautiful possibility of controlling pediatric HIV.
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Abstract: In many resource-limited settings a substantial pro-
portion of HIV-infected patients still commence antiretroviral
therapy (ART) with advanced HIV-related immunosuppression
with lowCD4+T-lymphocyte counts andactiveopportunistic infec-
tions. Such patients are at high risk for developing the immune
reconstitution inﬂammatory syndrome (IRIS) in the ﬁrst weeks to
months of ART as immune responses to opportunistic infection
antigens are rapidly restored resulting in inﬂammatory reactions
directed at antigens of the opportunistic infection. This may result
in hyper-inﬂammatory new presentations of opportunistic infec-
tions or paradoxical deterioration in patients already on treatment
for the opportunistic infection. IRIS is most commonly described in
association with mycobacterial, fungal and viral infections.
Tuberculosis-associated IRIS (TB-IRIS) is the most signiﬁcant
form of the condition encountered in settings where TB endemic.
In a recent meta-analysis, we found that TB-IRIS is reported in
18% (95%CI= 16-21%) of patients starting ART while on TB treat-
ment. Major risk factors for the condition are a low CD4 count,
high HIV viral load, disseminated TB and short interval between
starting TB treatment and ART. A key determining factor thus
appears to be antigen load. Innate and adaptive components of
the immune system have been shown to contribute. A gene tran-
scriptional signature characterised by innate immune signaling
genes distinguished patients who developed TB-IRIS from those
who did not, and was evident within a few days of starting ART
and prior to symptoms. TB-IRIS is characterized by high concentra-
tions of cytokines in peripheral blood, with elevated interleukin-6
identiﬁed consistently across studies. Common clinical presenta-
tions are worsening pulmonary inﬁltrates, enlarging lymph nodes
and abscess formation. Central nervous system involvement (eg.
meningeal inﬂammation, enlarging tuberculomas) may be life-
threatening. The average duration of the condition is 2-3 months,
but a small proportion of cases may have manifestations lasting > 1
year. We demonstrated in a previous clinical trial that prednisone
(starting at 1.5mg/kg/day) reduced hospitalization and improved
symptoms in patients with TB-IRIS. We are currently evaluating
prednisone for prevention of TB-IRIS in high-risk patients with TB
starting ART in a randomized placebo-controlled trial (PredART
trial: https://www.predart.org/site/index).
Cryptococcal IRIS typically presents with recurrent meningitis
in the ﬁrst months of ART, often with associated raised intracranial
pressure. No clinical trials have been conducted, but management
usually involves re-initiation of induction antifungal therapy until
